Actively Recruiting
Evaluating Patritumab Deruxtecan and Trastuzumab Deruxtecan Combination in Hormone Receptor-Positive, HER2-Low or Ultralow Unresectable or Metastatic Breast Cancer
Led by Daiichi Sankyo · Updated on 2026-10-01
220
Participants Needed
72
Research Sites
69 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and anti-tumor effects of two drugs, Patritumab Deruxtecan HER3-DXd and Trastuzumab Deruxtecan T-DXd, when used together in people with hormone receptor-positive, HER2-low or HER2-ultralow, unresectable, or metastatic breast cancer. This trial includes both dose regimen determination and dose expansion phases to find the optimal treatment combination and dose. Participants will receive one of several treatment regimens combination regimen A or B of HER3-DXd and T-DXd, a regimen based on earlier study data, or T-DXd alone. Treatments are given intravenously and continue until disease progression, unacceptable side effects, death, or trial closure. The study is randomized and open-label, meaning participants are assigned to different groups without masking. During the study, participants will be closely monitored for side effects and tumor response using imaging and laboratory tests over approximately 4.5 to 6 years. Researchers will assess treatment safety by recording adverse events and evaluate anti-tumor activity with standardized criteria. Blood samples will be collected at various times to measure drug levels. The study aims to find the best dosing while ensuring participant safety and treatment effectiveness over the long term.
CONDITIONS
Brief Title
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Research Team
D
Daiichi Sankyo Contact for Clinical Trial Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here